Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CC
Churchill Capital Corp XI Class A Ordinary Shares
CCXI
Mkt Cap
$593.7M
Volume
3.48M
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
CC
CCXI
CC
Churchill Capital Corp XI Class A Ordinary Shares
CCXI
News
·
Humanoid Global Provides Update on Agility Robotics Public Listing & Opens Silicon Valley AI Hub to Scale Digit Deployments
Mkt Cap
$593.8M
Volume
3.48M
Next Earnings
N/A
Chart
Earnings
News
About
Insider
Filings
Humanoid Global Provides Update on Agility Robotics Public Listing & Opens Silicon Valley AI Hub to Scale Digit Deployments
Agility Robotics, a portfolio company of Humanoid Global, has entered into a definitive business combination agreement with Churchill Capital Corp XI to go public in 2026 at a US$2.5 billion pre-money valuation, expected to raise over US$620 million. The company has secured over US$300 million in multi-year orders for its Digit v5 humanoid robot and opened a 60,000-square-foot Physical AI development hub in Fremont, California to accelerate deployment and add 200 technical roles.
GlobeNewswire Inc. · Jul 28, 2026
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November.
GlobeNewswire Inc. · Oct 17, 2022
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?
Here is how ChemoCentryx (CCXI) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.
Zacks Investment Research · Oct 6, 2022
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced two upcoming poster presentations for CCX559, the Company’s investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA.
GlobeNewswire Inc. · Oct 5, 2022
Is Invesco Dynamic Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Smart Beta ETF report for PBE
Zacks Investment Research · Sep 26, 2022
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Smart Beta ETF report for XBI
Zacks Investment Research · Sep 23, 2022
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Investment Research · Sep 8, 2022
Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?
ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks Investment Research · Sep 7, 2022
2 Top Biotech Stocks to Buy for the Long Haul
Both companies have outperformed the market over the past few decades.
The Motley Fool · Aug 24, 2022
ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical Conferences
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN).
GlobeNewswire Inc. · Aug 24, 2022
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
CC
CCXI
Churchill Capital Corp XI Class A Ordinary Shares
Buy
Sell
Market
Limit
Soon
CCXI
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any CCXI yet.
Related Tickers
Earnings